CHOP

WikiDoc Resources for CHOP
Articles
Most recent articles on CHOP Most cited articles on CHOP Review articles on CHOP Articles on CHOP in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on CHOP Images of CHOP Photos of CHOP Podcasts & MP3s on CHOP Videos on CHOP
Evidence Based Medicine
Cochrane Collaboration on CHOP Bandolier on CHOP TRIP on CHOP
Clinical Trials
Ongoing Trials on CHOP at Clinical Trials.gov Trial results on CHOP Clinical Trials on CHOP at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on CHOP NICE Guidance on CHOP NHS PRODIGY Guidance FDA on CHOP CDC on CHOP
Books
Books on CHOP
News
CHOP in the news Be alerted to news on CHOP News trends on CHOP
Commentary
Blogs on CHOP
Definitions
Definitions of CHOP
Patient Resources / Community
Patient resources on CHOP Discussion groups on CHOP Patient Handouts on CHOP Directions to Hospitals Treating CHOP Risk calculators and risk factors for CHOP
Healthcare Provider Resources
Symptoms of CHOP Causes & Risk Factors for CHOP Diagnostic studies for CHOP Treatment of CHOP
Continuing Medical Education (CME)
CME Programs on CHOP
International
CHOP en Espanol CHOP en Francais
Business
CHOP in the Marketplace Patents on CHOP
Experimental / Informatics
List of terms related to CHOP

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

CHOP is the acronym for a chemotherapy regimen used in the treatment of non-Hodgkin lymphoma. CHOP stands for Cytoxan, Hydroxydaunorubicin (Adriamycin), Oncovin (Vincristine), Prednisone/Prednisolone.

Uses and indications

CHOP consists of:

• Cyclophosphamide
• Hydroxydaunorubicin (alternative name) - doxorubicin
• Oncovin® (brand name) - vincristine
• Prednisone or Prednisolone.

This regimen can also be combined with the monoclonal antibody rituximab if the lymphoma is of B cell origin (R-CHOP or CHOP-R). Typically, courses are administered at an interval of three weeks. A staging CT scan is generally performed after three cycles to assess whether the disease is responding to treatment.

In patients with a history of cardiovascular disease, the doxorubicin (which is cardiotoxic) is often deemed to be too great a risk and is omitted from the regimen. The combination is then referred to as COP or CVP.

Side-effects and complications

The combination is generally well tolerated. Chemotherapy-induced nausea and vomiting may require antiemetics (such as ondansetron), and hemorrhagic cystitis is prevented with administration of mesna. Alopecia (hair loss) is common.

Neutropenia generally develops in the second week. During this period, many clinicians recommend prophylactic use of ciprofloxacin. If a fever develops in the neutropenic period, urgent medical assessment is required for neutropenic sepsis, as infections in patients with low neutrophil counts may progress rapidly.

Allopurinol is typically co-administered prophylactically to prevent tumor lysis syndrome, the result of rapid death of tumor cells.

History

A pivotal study published in 1993 compared CHOP to several other chemotherapy regimens (e.g. m-BACOD, ProMACE-CytaBOM, MACOP-B). CHOP emerged as the regimen with the least toxicity but similar efficacy.

See also

• Chemotherapy regimens

References

1. ^ Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A (2005). "Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas". N Engl J Med. 353 (10): 988–98. PMID 16148284.CS1 maint: Multiple names: authors list (link)
2. ^ Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993). "Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma". N Engl J Med. 328 (14): 1002–6. PMID 7680764.CS1 maint: Multiple names: authors list (link)

de:CHOP fi:CHOP